Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;135(7):2291-2298.
doi: 10.1002/lary.32061. Epub 2025 Feb 12.

Otolaryngologic Side Effects of GLP-1 Receptor Agonists

Faizaan I Khan  1 , Sebastian Guadarrama-Sistos Vazquez  1   2 , Zain Mehdi  2 , Isuru Somawardana  1 , Roshan Dongre  1 , Samuel Razmi  1 , Keyvon Rashidi  1 , Jason Shenoi  1 , Najm Khan  2 , Aatin Dhanda  2 , Masayoshi Takashima  2 , Omar G Ahmed  2
Affiliations

Otolaryngologic Side Effects of GLP-1 Receptor Agonists

Faizaan I Khan et al. Laryngoscope. 2025 Jul.

Abstract

Objectives: With the increasing use of GLP-1 receptor agonist (GLP-1 RA) drugs for weight loss and diabetes management, concerns have been raised regarding their potential side effects. We aim to assess the frequency of otolaryngologic adverse events (AEs).

Study design: Retrospective analysis of national registry.

Methods: The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023. AEs were collected and sub-stratified according to anatomic site. Reporting odds ratios (ROR) and proportional reporting ratios (PRR) were determined for all AEs.

Results: The number of AEs reported from all drugs within this study totaled 9,746. Significant signal ratios were defined as a PRR≥2 and a lower CI ROR >1. Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) had the highest signals and were significant in virtually all medications. This was followed by GERD which also had very high signal ratios and was significant in all drugs assessed. Semaglutide also had significant signals in anosmia, dry mouth, dysgeusia, and Bell's palsy. Liraglutide had significance in both signals in dysphonia, dysgeusia, tinnitus, and Bell's palsy. This was followed by exenatide which also included dysgeusia and hearing disability.

Conclusions: GLP-1 RA were associated with various otolaryngologic AEs, with significant signals observed for semaglutide and liraglutide. GERD, MTC, and PTC were of significance in all GLP-1 RA in this study. Monitoring these AEs is recommended.

Level of evidence: 4 Laryngoscope, 135:2291-2298, 2025.

Keywords: GLP‐1; Ozempic; diabetes; side effects; weight loss.

PubMed Disclaimer

References

BIBLIOGRAPHY

    1. Medications containing semaglutide marketed for type 2 diabetes or weight loss. FDA. 2023. Accessed December 20, 2023 https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-an....
    1. Meier JJ. GLP‐1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728‐742.
    1. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon‐like peptide‐1 receptor agonists on weight loss: systematic review and meta‐analyses of randomised controlled trials. BMJ. 2012;344:d7771.
    1. McPhillips D. CNN exclusive: prescriptions for popular diabetes and weight‐loss drugs soared, but access is limited for some patients. CNN. 2023. Accessed December 20, 2023 https://www.cnn.com/2023/09/27/health/semaglutide-equitable-access/index....
    1. Lee JM, Sharifi M, Oshman L, Griauzde DH, Chua KP. Dispensing of glucagon‐like Peptide‐1 receptor agonists to adolescents and young adults, 2020‐2023. JAMA. 2024;331:2041‐2043. https://doi.org/10.1001/jama.2024.7112.

MeSH terms

LinkOut - more resources